Αποτελέσματα Αναζήτησης
14 Απρ 2022 · The past decade has seen significant advances in stroke prevention. These advances include new antithrombotic agents, new options for dyslipidemia treatment, and novel techniques for surgical stroke prevention.
25 Ιουλ 2022 · This systematic review examined the quality of the evidence for early anticoagulation therapy (started within 2 weeks of stroke onset) compared with control in people with AIS. 1 The primary outcome was death or dependency, at least 1 month after stroke.
25 Φεβ 2015 · New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Unlike VKAs, these anticoagulants do not require routine INR monitoring and possess favorable pharmacological properties.
28 Μαΐ 2024 · Atrial fibrillation (AF) increases the risk of ischemic stroke, accounts for about one quarter of all ischemic strokes worldwide, and is associated with a substantial morbidity and mortality. 1 Oral anticoagulation can reduce the stroke risk in nonvalvular AF by two thirds by using vitamin K antagonists or non‐vitamin K‐dependent oral anticoagul...
12 Οκτ 2020 · With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
17 Ιουν 2022 · Quick Takes. Factor XIa inhibition may reduce stroke risk but preserve patients' ability to clot when bleeding. Phase 2 trial PACIFIC-AF showed a significant two-thirds reduction in significant bleeding with asundexian, an oral factor XIa inhibitor, in comparison to apixaban.
15 Φεβ 2024 · Current anticoagulant therapies are associated with up to 2 % of hemorrhagic strokes. •. New antithrombotic therapies are needed for primary and secondary prevention of AIS. Abstract. Acute ischemic stroke (AIS) is the most common type of stroke and requires immediate reperfusion.
